Scholarlink

<p>17-β-hydroxysteroid dehydrogenase 4 (HSD17B4), abundantly present in the peroxisomal regions of mammalian cells, is an oxidoreductase that catalyzes the oxidoreduction of steroid substrates. Impairment of lipid metabolism represents one of the most critical metabolic alterations in cancer, with lipid metabolic processes tightly linked to tumor cell proliferation, survival, invasion, and metastasis. HSD17B4 is primarily involved in the regulation of cellular fatty acid and hormone metabolism. Therefore, HSD17B4 is closely related to tumors, but few relevant studies exist. Polymorphisms and methylation of the <i>HSD17B4</i> gene, as well as acetylation of the HSD17B4 protein, influence its expression and function, impacting cancer progression and therapeutic response. Recent findings also highlight HSD17B4 as a potential therapeutic target and prognostic biomarker in various cancers. Here, we will discuss the latest literature on human HSD17B4 and its clinical implications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Deciphering 17-β-hydroxysteroid dehydrogenase 4: from molecular insights to cancer therapeutics

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月19日

查看全文
  • Meng-Bin Liao,
  • Andy T. Y. Lau,
  • Yan-Ming Xu

摘要

17-β-hydroxysteroid dehydrogenase 4 (HSD17B4), abundantly present in the peroxisomal regions of mammalian cells, is an oxidoreductase that catalyzes the oxidoreduction of steroid substrates. Impairment of lipid metabolism represents one of the most critical metabolic alterations in cancer, with lipid metabolic processes tightly linked to tumor cell proliferation, survival, invasion, and metastasis. HSD17B4 is primarily involved in the regulation of cellular fatty acid and hormone metabolism. Therefore, HSD17B4 is closely related to tumors, but few relevant studies exist. Polymorphisms and methylation of the HSD17B4 gene, as well as acetylation of the HSD17B4 protein, influence its expression and function, impacting cancer progression and therapeutic response. Recent findings also highlight HSD17B4 as a potential therapeutic target and prognostic biomarker in various cancers. Here, we will discuss the latest literature on human HSD17B4 and its clinical implications.